As per MRFR Analysis, the Renal Disease Market was valued at USD 3.6 billion in 2023 and is projected to grow to USD 7.42 billion by 2032, with a CAGR of 9.70% from 2024 to 2032. The market growth is driven by increasing cases of diabetes and hypertension, along with the rising prevalence of chronic kidney disease. Key developments include a licensing deal between Zydus Lifesciences and Sun Pharma for a novel oral treatment for anemia in CKD patients, and Novartis's positive Phase III results for atrasentan in IgAN patients, indicating significant advancements in treatment options.
The renal disease market is experiencing significant growth due to various health trends and advancements in treatment.
Key companies include Abbott, Amgen Inc., AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, GlaxoSmithKline, Keryx Biopharmaceuticals, Kissei Pharmaceutical, and Novartis.
The increasing cases of diabetes & hypertension and the rising prevalence of chronic kidney disease are the key market drivers boosting the growth of the renal disease market.
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
In October 2023, Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited (Sun Pharma) inked a licensing deal to jointly commercialize a novel pharmaceutical. The purpose of this collaboration is to enhance the treatment of patients suffering from anemia resulting from renal illness. Desidustat, according to its developers, is the inaugural oral pharmaceutical in India specifically designed to treat anemia resulting from chronic kidney disease (CKD).
Zydus has granted a semi-exclusive comarketing license to Sun Pharma for the RYTSTAT brand in India, as per the conditions of the agreement. Zydus debuted the medicine Oxemia under its brand name in 2022, and the business intends to continue its sales. Zydus will receive upfront license payments and further compensation upon achieving specified milestones.
In October 2023, Novartis announced positive initial results from the ongoing pivotal Phase III ALIGN study of atrasentan, an oral endothelin A receptor antagonist (ERA), in patients with IgAN. The safety profile of atrasentan in the trial was consistent with the safety profile observed in the IgAN cohort of the Phase II AFFINITY investigation, which had been previously documented.
Novartis plans to file an application for accelerated approval in the US in 2024, using the results of this intermediate proteinuria endpoint trial. The notable reduction in proteinuria observed in this study's Phase III results demonstrates the potential of atrasentan to improve outcomes for individuals with IgAN. Their portfolio consists of three advanced therapeutics for IgAN, which have distinct characteristics. These therapies have the potential to offer valuable treatment choices for those suffering from this incapacitating condition. One of these medicines, iptacopan, has recently demonstrated good results in its Phase III trial.
Diabetes, hypertension, and kidney failure are three conditions that are closely related and impact each other. The millions of minuscule filtering units within each kidney are damaged over time by excessive amounts of sugar in the blood, leading to kidney failure. According to a report by The International Diabetes Federation (IDF), in March 2020, 13.3% of the total population of the US approximately around 30,987,900 people are diabetic. IDF also predicts that by 2045, the North America and Caribbean (NAC) region will have 63 million diabetic people in the region.
Furthermore, hypertension also negatively impacts proper kidney functioning. Uncontrolled high blood pressure can narrow, weaken, or stiffen the arteries surrounding the kidneys over time. These arteries cannot carry enough oxygenated blood to the renal tissue due to their impairment causing kidney tissue damage. According to the National Kidney Foundation, uncontrolled high blood pressure is the second leading cause of kidney failure in the US.
In addition, according to the Centers for Disease Control and Prevention (CDC), hypertension is a primary cause of stroke, heart attack, and renal failure. Hypertension, obesity, diabetes, and heart failure were responsible for 64 % of Covid-19 hospitalizations during the pandemic. Obese people are also more likely to develop hypertension. Therefore, increasing diabetes and hypertension cases across the globe increases the demand for dialysis, anti-hypertensive & diabetes medication, and Kidney transplantation leading to the growth of the renal disease market.
The renal disease market segmentation, based on disease type, includes chronic kidney disease, and end-stage renal disease. The chronic kidney disease type segment held the majority share in 2022 in respect to the renal disease market revenue. Chronic Kidney Disease (CKD), also called chronic kidney failure, is characterized by loss of kidney function over time. The main risk factors for CKD are high blood pressure, diabetes, and heart disease. According to the National Kidney Foundation, the treatment of chronic kidney disease is likely to exceed USD 48 billion per year in the US.
The renal disease market segmentation, based on treatment, includes dialysis, medication, and kidney transplantation. The dialysis segment dominated the market in 2022 in respect to the renal disease market. Dialysis is the removal of waste products and excess fluid such as water, solutes, and toxins from the blood when the kidneys stop working properly. It is generally performed when 85-90% of kidney function is gone, GFR falls below 15, and kidneys no longer work well enough to sustain a patient’s body.
According to the 2023 Annual Data Report by the United States Renal Data System (USRDS), indicates that over 809,000 Americans are living with end-stage kidney disease (ESKD). Out of these, approximately 555,000 patients are undergoing dialysis treatment, while the remainder have received kidney transplants. The dialysis segment involves
, erythropoiesis-stimulating agents (ESAs), potassium binders, and phosphate binders. Antihypertensive drugs are used to lower the high blood pressure of the patient.
June 2024:
Abbott has launched a next-generation portable dialysis device, featuring advanced sensors and connectivity for real-time monitoring of treatment effectiveness, aiming to enhance patient adherence and outcomes in chronic kidney disease patients.
May 2024:
Amgen has introduced a new oral medication, a phosphate binder, for managing hyperphosphatemia in dialysis patients, showing superior efficacy, safety, and fewer side effects compared to existing treatments.
July 2024:
Novartis has released a novel immunosuppressant for kidney transplantation patients, reducing organ rejection risk and minimizing long-term effects, using a targeted mechanism of action.
The renal disease market segmentation, based on indication includes dialysis centers, hospital & clinics, and research and academic institutes. The dialysis centers held the largest market share in 2022 with respect to the renal disease market revenue. Dialysis centers provide dialysis for patients with chronic kidney failure. In dialysis centers, trained nurses and technicians perform the procedure on patients with renal diseases.
December 2020 GlaxoSmithKline plc (UK) received the US Food and Drug Administration (FDA) approval for BENLYSTA (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard therapy Figure 2 Renal Disease Market, by End User, 2022 & 2032 (USD Billion) 
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
By region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. North America Renal Disease held the largest market share in 2022. This is attributed to the rising prevalence of kidney disease, the growing prevalence of diabetes and hypertension, and the rapid growth in the geriatric population.
Further, the major countries studied are The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 3 Renal Disease Market Share (%) By Region 2022 
Source Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe renal disease market accounts for the second-largest market share due to the increasing healthcare spending, various government initiatives & awareness campaigns regarding CKD, availability of technologically advanced products, and the presence of newly established state-of-the-art healthcare facilities in the region. Further, the Germany renal disease market held the largest market share, and the UK renal disease market was the fastest-growing market in the European region.
The Asia-Pacific renal disease market is expected to grow at a significant growth rate during the forecast period. This is due to the factors, such as growth in the aging population, various lifestyle stress, a large population base, improving quality of diagnosis, and growing patient affordability are factors expected to boost the market over the forecast period. Moreover, China renal disease market held the largest market share, and the India renal disease market was the fastest-growing market in the Asia-Pacific region. Hence, Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2024–2032.
Renal Disease Key Market Players & Competitive Insights
Major market players are spending a lot of money on R&D to increase their product lines, which will help the renal disease market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the renal disease industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.
One of the primary business strategies adopted by manufacturers in the renal disease industry to benefit clients and expand the renal disease market sector is to manufacture locally to reduce operating costs.
Akebia Therapeutics Inc. (US) is a trusted leader in the renal community delivering unique products to people suffering from kidney disease. Its product Vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to Vadadustat, the company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Keryx Biopharmaceuticals is a subsidiary of Akebia Therapeutics.
For instance, in June 2021, Akebia Therapeutics, Inc. collaborated with Otsuka Pharmaceutical Co., Ltd. (Japan) Ostuka company also announced the US Food and Drug Administration (FDA) accepted filing the New Drug Application (NDA) for vadadustat for the treatment of anemia due to chronic kidney disease (CKD) in both adult patients on dialysis and adult patients not on dialysis.
Key Companies in the Renal Disease Market Includes
Renal Disease Industry Developments May 2021 Bristol Myers Squibb (US) declared that OPDIVO (nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks in combination with CABOMETYX (cabozantinib) 40 mg once daily tablets was approved by the US Food and Drug Administration (FDA) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) January 2021 Fresenius Medical Care (Germany) announced that the company's Frenova division has enrolled the first participants in Colombia as its new initiative to develop the largest renal-focused genomic registry in the world. The renal-focused genomic registry represents a new business line within Frenova, based in Fresenius Medical Care's Medical Office June 2021 Novartis AG (Switzerland) announced positive new interim Phase II data showing investigational iptacopan (LNP023), a first-in-class, oral, targeted factor B inhibitor improved estimated glomerular filtration rate (eGFR) slope and stabilized kidney function in patients with C3 glomerulopathy (C3G) treated with iptacopan
| Attribute/Metric | Details |
| Market Size 2023 | USD 3.6 billion |
| Market Size 2024 | USD 3.9 billion |
| Market Size 2032 | USD 7.41 billion |
| Compound Annual Growth Rate (CAGR) | 9.7% (2024-2032) |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2019-2022 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Disease Type, Treatment Type, End User and Region |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Abbott (US), Amgen Inc. (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer Inc. (US), GlaxoSmithKline PLC (UK), Keryx Biopharmaceuticals, Inc. (US), Kissei Pharmaceutical Co., Ltd. (Japan), Novartis (Switzerland) |
| Key Market Opportunities | Growing geriatric population |
| Key Market Dynamics | Increasing cases of diabetes and hypertension Rising prevalence of chronic kidney disease |
Renal Disease Market Highlights:
Frequently Asked Questions (FAQ) :
The renal disease market is anticipated to reach USD 7.41 billion at a CAGR of 9.7% during the forecast period of 2024 to 2032.
The US Renal Disease Market share is 35-40% during the forecast period of 2024 to 2032
The Renal Disease market is expected to register a CAGR of 9.7% during the forecast period of 2024 to 2032.
North America held the largest market share in the renal disease market.
Abbott (US), Amgen Inc. (US), AstraZeneca (UK), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd. (Switzerland)
The dialysis segment led the renal disease market.
The dialysis centers end user led the renal disease market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
